Investors Urged to Join Class Action Against Allarity Therapeutics

LOS ANGELES, Oct. 28, 2024 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. (“Allarity” or “the Company”) ALLR. The firm alleges violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.

Investors who purchased the Company’s securities between May 17, 2022, and July 19, 2024, are encouraged to contact the firm before November 12, 2024.

If you are a shareholder who suffered a loss, click here to participate.

You can also reach out to Brian Schall at the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335. To learn more, visit www.schallfirm.com or email bschaI1@schallfirm.com.

It’s important to note that the class action has not yet been certified. Until that happens, individuals are not represented by an attorney. Those who do not take action may remain absent class members.

The Complaint alleges that the Company made false and misleading statements. It claims that Allarity and its executives were involved in illegal and inappropriate conduct concerning the Dovitinib NDA and/or the Dovitinib-DRP PMA. These actions exposed the Company to heightened regulatory and legal risks. Additionally, it is alleged that Allarity minimized the possibility of enforcement actions even after an investigation was announced. Consequently, the Company’s public statements during the class period were considered false and misleading, resulting in damages when the truth was revealed.

Join the case to pursue recovery for your losses.

The Schall Law Firm has a global practice focused on securities class action lawsuits and protecting shareholder rights.

This communication could be classified as Attorney Advertising in some jurisdictions based on relevant laws and ethics rules.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/allr-investors-have-opportunity-to-lead-allarity-therapeutics-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302288212.html

SOURCE: The Schall Law Firm